NCT02867033 2026-03-18
ALTITUDES
Centre Oscar Lambret
Phase NA Active not recruiting
Clinical Trials
50 trialsNCT05960578 2026-03-12
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
University of Washington
Phase 2 Active not recruiting
NCT01334021 2026-03-09
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03941730 2026-03-05
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04708067 2026-03-05
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05035706 2026-03-05
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT05166616 2026-03-05
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06203912 2026-03-05
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04764942 2026-02-25
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Mayo Clinic
Phase 1/2 Active not recruiting
NCT03179904 2026-02-24
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT06178588 2026-02-24
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT05677919 2026-02-12
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 2 Active not recruiting
NCT03120624 2026-02-04
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
Mayo Clinic
Phase 1 Active not recruiting
NCT05497804 2026-02-03
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Mayo Clinic
Phase 2 Active not recruiting
NCT02312401 2026-01-29
Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06169267 2026-01-28
Passive Music Intervention for the Reduction of Anxiety in Patients Undergoing Bone Marrow Aspiration and/or Biopsy
City of Hope Medical Center
Phase 3 Active not recruiting
NCT07352748 2026-01-28
MOSAIC
Universita di Verona
Active not recruiting
NCT04767984 2026-01-21
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
Northwestern University
Phase 2 Active not recruiting
NCT06056895 2026-01-15
TRICK-MCC
University of Washington
Phase 2 Active not recruiting
NCT04095364 2026-01-14
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT04673448 2026-01-09
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1 Active not recruiting
NCT02210117 2026-01-07
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT04729322 2025-12-23
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07031765 2025-12-18
Peds CHAMP1ON
University of Florida
Phase 1 Active not recruiting
NCT05267912 2025-12-16
ORGANOTREAT
Gustave Roussy, Cancer Campus, Grand Paris
Phase NA Active not recruiting
NCT05564650 2025-12-08
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
Phase 1 Active not recruiting
NCT01991379 2025-12-04
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT05874726 2025-12-02
Biological Sample Repository for Gastrointestinal Disorders
Brigham and Women's Hospital
Active not recruiting
NCT05034627 2025-11-28
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 1 Active not recruiting
NCT01093612 2025-11-14
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT05074264 2025-11-10
CAMPO-101
University of California, San Francisco
Phase NA Active not recruiting
NCT05718869 2025-11-04
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02790853 2025-10-14
Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04931017 2025-10-07
Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer
Northwestern University
Phase 2 Active not recruiting
NCT05237960 2025-09-29
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
University of Arizona
Phase 2 Active not recruiting
NCT05699603 2025-09-24
Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients
University of Arizona
Phase 2 Active not recruiting
NCT05359211 2025-09-15
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Active not recruiting
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05507541 2025-08-29
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
Phase 2 Active not recruiting
NCT05242965 2025-08-24
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
University of Washington
Phase 2 Active not recruiting
NCT01361711 2025-05-23
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Northwestern University
Phase 2 Active not recruiting
NCT03281902 2025-03-06
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
Mayo Clinic
Active not recruiting
NCT03077776 2025-02-20
TRACERX-TNBC
UNICANCER
Phase NA Active not recruiting
NCT03412058 2025-02-20
CHECK'UP
UNICANCER
Phase NA Active not recruiting
NCT03757689 2025-02-11
Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
Abramson Cancer Center at Penn Medicine
Phase 2 Active not recruiting
NCT05228197 2025-01-22
IP6-CHAIROS
Imperial College London
Active not recruiting
NCT04719988 2024-12-20
INTERACT-ION
Centre Hospitalier Universitaire de Besancon
Phase 2 Active not recruiting
NCT03519048 2024-03-26
SURVEILL'ORL
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Active not recruiting
NCT03089268 2023-10-02
SERRACOLON
Hospital Universitario La Fe
Active not recruiting